Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ad5 [E1-, E2b-]-HER2/Neu vaccine ETBX-021

A cancer vaccine composed of a genetically engineered, replication-defective oncolytic adenovirus serotype 5 (Ad5) vector, in which the E1, E2b and E3 genes are deleted, that encodes a modified version of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2/neu; ErbB-2; ERBB2), with potential antineoplastic activity. Upon administration of Ad5 [E1-, E2b-]-HER2/neu ETBX-021, the vector expresses HER2/neu and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER2/neu antigen. This results in the immune-mediated induction of death in and inhibition of proliferation of HER2/neu-expressing tumor cells. HER2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types while expression is restricted and minimal in certain normal healthy cells. It plays a key role in cancer cell proliferation and survival. The gene deletions in Ad5 may circumvent pre-existing anti-adenovirus immunity, allow HER2 gene insertion and expression and induce a strong immune response.
Synonym:Ad5 [E1-, E2b-]-HER2/neu vaccine
adenovirus type 5 E1/E2b-deleted HER2/neu vaccine ETBX-021
Code name:ETBX-021
Search NCI's Drug Dictionary